BOSTON, July 11, 2024 (GLOBE NEWSWIRE) -- Novotech, the global full-service
clinical Contract Research Organization (CRO) that partners with biotech
companies to accelerate the development of advanced and novel therapeutics at
every phase, has today released a significant research report entitled Chronic
Lymphocytic Leukemia (CLL) - Global Clinical Trial Landscape (https://novotech-
cro.com/reports/chronic-lymphocytic-leukemia-global-clinical-trial-landscape-
2024).
This expert monthly report, provided by the Novotech research analyst team, is
free of charge. It highlights promising new developments in CLL research and
therapies, offering industry-leading and in-depth analysis of the disease's
epidemiology, clinical trial activity, treatment options, and funding landscape.
The analysis identifies the exciting progress being made in CLL research, and
key opportunities for advancing treatment strategies globally.
CLL, a slow-growing leukemia affecting older adults, has shown diverse
epidemiological patterns across different regions. In 2022, an estimated
121,000 CLL cases were documented globally, with Europe and North America
accounting for the majority. Europe reported close to 32,000 cases, led by
Germany with 4,500 cases. The United States alone contributed approximately
19,000 cases.
The incidence of CLL in Asia is generally lower than in Western countries, with
China reporting 10 to 20 times fewer cases than the United States. Asia has an
estimated nearly 11,000 cases, with China and India accounting for around 4,000
and 2,000 cases, respectively. In other Asian locations, including Japan, the
Philippines, Thailand, South Korea, and Malaysia, the collective estimated CLL
incidence surpassed 1,500 cases.
Treatment for CLL varies based on genetic markers, disease stage, and prior
treatment responses. The National Comprehensive Cancer Network (NCCN) and the
European Society for Medical Oncology (ESMO) provide guidelines that emphasize
targeted therapies and immunotherapies. The development of drugs like Bruton's
Tyrosine Kinase inhibitors (BTKis) and BCL-2 inhibitors, as well as advancements
in CAR T-cell therapy, represent significant strides in improving patient
outcomes.
The clinical trial landscape for CLL shows a robust global effort to advance
treatment options and understand the disease. Since 2019, over 1,000 clinical
trials have been initiated worldwide, with North America leading at 37% of these
trials, followed closely by the Asia-Pacific region at 34%, Europe at 20%, and
the rest of the world (ROW) at 8%. Within North America, the United States hosts
the vast majority, accounting for 85% of all North American trials. In Asia-
Pacific, Mainland China plays a pivotal role, conducting 44% of trials in the
region and in Europe Novotech's research found significant participation from
countries like Spain, France, and Italy.
Interestingly, despite the lower incidence of CLL in Asian countries, the report
uncovered that the Asia-Pacific region exhibits a trial density about seven
times lower than the United States and approximately three times lower than
Europe. This discrepancy highlights both the potential for increased research
engagement in Asia-Pacific countries and the relative concentration of clinical
trial activity in more densely populated regions.
The report also provides a SWOT analysis, highlighting the strengths in targeted
therapies and advanced diagnostics. Opportunities lie in next-generation
therapies and personalized treatment approaches, while challenges include high
treatment costs and potential drug resistance.
Key takeaways from the report (https://novotech-cro.com/reports/chronic-
lymphocytic-leukemia-global-clinical-trial-landscape-2024):
* The average enrolment period in the United States is 43.92 months,
significantly longer than Asia-Pacific's 21.70 months, yet both regions show similar recruitment efficiency.
* CLL drug development includes 24 drugs in preclinical stages, 33 in Phase I,

    30 in Phase II, and 4 in Phase III. Additionally, 5 drugs have received
    approval, and 26 are already marketed.
  * The majority of marketed drugs for CLL are DNA Synthesis inhibitors and B
    Lymphocyte Antigen CD20 inhibitors. Bruton Tyrosine Kinase inhibitors
    dominate ongoing Phase III trials.
  * From 2019 to 2023, China led venture capital funding for CLL research with

$1,813 million, followed closely by the United States with $1,805.6 million. The CLL Society and the CLL Foundation in the United States play significant

    roles in funding CLL research and supporting patients.
  * Significant advancements outlined in the report in targeted therapies,

immunotherapy (CAR T-cell therapy), and precision medicine have improved CLL

    treatment outcomes. Companies like AbbVie Inc., BeiGene Ltd., and Celltrion
    Inc. are actively developing new therapies, paving the way for improved
    management of this complex disease.
  * Future research is exploring mitochondrial, glucose, glutamine, and lipid
    pathways as therapeutic targets, while high treatment costs and potential
    drug resistance pose challenges.

Download the report here (https://novotech-cro.com/reports/chronic-lymphocytic-
leukemia-global-clinical-trial-landscape-2024)
About Novotech Novotech-CRO.com (https://novotech-cro.com/)
Founded in 1997, Novotech is a global full-service clinical Contract Research
Organization (CRO) focused on partnering with biotech companies to accelerate
the development of advanced and novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has received
numerous prestigious awards, including the CRO Leadership Award 2023, the Asia
Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific
Contract Research Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including laboratories,
Phase I facilities, drug development consulting, regulatory expertise, and has
experience with over 5,000 clinical projects, including Phase I to Phase IV
clinical trials and bioequivalence studies. With a presence in 34 office
locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a
trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member visit www.Novotech-
CRO.com (http://www.Novotech-CRO.com)
Â